Insofar as it is clear that the virus can be transmitted by vaccinated persons, and the overall mortality risk is very low for more than 99% of people, such a move would only put money into big pharma's hands, while depriving citizens of the commonwealth their right to bodily autonomy.

The ethic of informed medical consent includes the right of individuals to  accept or to decline a pharmaceutical product or medical intervention.  This right has been universally affirmed as a human right by ethicists, medical societies, Virginia regulation, institutional patient bills of rights, and the United Nations Universal Declaration of Human Rights.

Phase III clinical trials for the available COVID-19 shots will not be completed until April 6, 2023 (Pfizer/BioNTech), February 14, 2023 (Moderna) and January 3, 2023 (Johnson and Johnson).

 These are new pharmaceutical products and there are no animal studies or long term safety profiles.  Specifically, it is not known whether these experimental products may cause autoimmune disease, allergy, cancer, reproductive harm, or cardiac, vascular or neurodevelopmental disorders.  The migration of the spike protein to a wide variety of organs, crossing the blood/brain and placental barrier are significant considerations that demand a very cautious approach. A mandate would NOT be a cautious approach.

Additionally, the natural immunity of those individuals who have recovered from COVID-19 has been shown to be robust and durable.